Simvastatin pretreatment reduces caspase-9 and RIPK1 protein activity in rat cardiac allograft ischemia-reperfusion
详细信息 查看全文
- 作者：Raimo Tuuminena ; 1 ; raimo.tuuminen@helsinki.fi" class="auth_mail" title="E-mail the corresponding author ; Emil Holmströ ; ma ; 1 ; Alireza Raissadatia ; Pipsa Saharinenb ; Eeva Rouvinena ; Rainer Krebsa ; Karl B. Lemströ ; ma
- 关键词：APC ; antigen-presenting cell ; c-FLIP ; cellular FLICE-inhibitory protein ; DAMP ; damage-associated molecular pattern ; EC ; endothelial cell ; IRI ; ischemia/reperfusion injury ; LDH ; lactate dehydrogenase ; PGD ; primary graft dysfunction ; RIPK1/3 ; receptor-interacting protein kinase-1 and -3 ; TNF ; tumor necrosis factor ; Tx-IRI ; transplant ischemia/reperfusion injury
- 刊名：Transplant Immunology
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：37
- 期：Complete
- 页码：40-45
- 全文大小：1186 K
文摘
- •
Current immunosuppressive therapies target recipient T cell mediated adaptive immunity.
- •
Donor treatment is a fascinating approach to prophylactically target Tx-IRI induced cell death and induction of allograft immunogenicity.
- •
Anti-apoptotic and anti-necroptotic properties of simvastatin could be exploited in expansion of the donor pool and improvement of the transplant quality.